Document Detail

Efficacy and safety of moclobemide compared with imipramine in the treatment of major depressive disorder. Double-blind multicenter study, Austria.
MedLine Citation:
PMID:  2089087     Owner:  NLM     Status:  MEDLINE    
In a double-blind, 4-week, prospective, randomized multicenter (17 centers) study we checked on the efficacy, tolerability and safety of moclobemide (300-600 mg/d) compared to imipramine (100-200 mg/d) in parallel groups of patients with a Major Depressive Episode (DSM III). The mean % reduction of the HAMD at the end of treatment was 51.7 in the moclobemide group and 52.1 in the imipramine group. The percentage of patients in whom efficacy was globally judged as "good" or "very good" was 62% in the moclobemide group and 60% in the imipramine group. There was no statistically significant difference in the efficacy in both groups but in some factors there was a trend for a better amelioration favoring moclobemide. The final overall physician's judgement of tolerability was "good" or "very good" in 83% of moclobemide patients and in 74% of imipramine patients. Adverse events were reported or observed in 56% of moclobemide patients and in 69% of imipramine patients. The number of mild, moderate and severe adverse events was higher in the imipramine group with a total of 286 versus 189. There was a statistically high significant difference considering the tolerability favoring moclobemide again. In this project the basic goal to find a substance with at least the same efficacy but a much better tolerability for sure got fulfilled.
G F Hebenstreit; M Loidl; U Baumhackl; B Gallhofer; C Geretsegger; E Radmayr; M Saletu; W Schöny; M Stabl
Related Documents :
2646087 - Effect of ranitidine on gastroduodenal mucosal damage induced by nonsteroidal antiinfla...
16498377 - Ranitidine in the prevention of gastroduodenal damage during antiblastic polychemotherapy.
6119777 - A double-blind endoscopically controlled trial of ranitidine in a high incidence area.
2880457 - Remoxipride in schizophrenia. a preliminary report.
15933977 - The effect of acute normovolaemic haemodilution on the inflammatory response and clinic...
22419617 - High mucosal healing rates in 5-asa-treated ulcerative colitis patients: results of a m...
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial    
Journal Detail:
Title:  Journal of neural transmission. Supplementum     Volume:  32     ISSN:  0303-6995     ISO Abbreviation:  J. Neural Transm. Suppl.     Publication Date:  1990  
Date Detail:
Created Date:  1991-05-29     Completed Date:  1991-05-29     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0425126     Medline TA:  J Neural Transm Suppl     Country:  AUSTRIA    
Other Details:
Languages:  eng     Pagination:  177-84     Citation Subset:  IM    
NO Landes-Nervenklinik, Amstetten/Mauer, Switzerland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Benzamides / adverse effects,  therapeutic use*
Depressive Disorder / drug therapy*,  psychology
Double-Blind Method
Imipramine / adverse effects,  therapeutic use*
Middle Aged
Monoamine Oxidase Inhibitors / therapeutic use*
Prospective Studies
Psychiatric Status Rating Scales
Reg. No./Substance:
0/Benzamides; 0/Monoamine Oxidase Inhibitors; 50-49-7/Imipramine; 71320-77-9/Moclobemide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Does moclobemide stimulate melatonin synthesis as the other selective MAO-A inhibitors do?
Next Document:  Psychometric alterations in treatment with the MAO-A-inhibitor moclobemide.